ID   HINT1_HUMAN             Reviewed;         126 AA.
AC   P49773; Q9H5W8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   04-FEB-2015, entry version 149.
DE   RecName: Full=Histidine triad nucleotide-binding protein 1;
DE            EC=3.-.-.-;
DE   AltName: Full=Adenosine 5'-monophosphoramidase;
DE   AltName: Full=Protein kinase C inhibitor 1;
DE   AltName: Full=Protein kinase C-interacting protein 1;
DE            Short=PKCI-1;
GN   Name=HINT1; Synonyms=HINT, PKCI1, PRKCNH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8812426; DOI=10.1006/geno.1996.0435;
RA   Brzoska P.M., Chen H., Levin N.A., Kuo W.L., Collins C., Fu K.K.,
RA   Gray J.W., Christman M.F.;
RT   "Cloning, mapping, and in vivo localization of a human member of the
RT   PKCI-1 protein family (PRKCNH1).";
RL   Genomics 36:151-156(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7644499; DOI=10.1073/pnas.92.17.7824;
RA   Brzoska P.M., Chen H., Zhu Y., Levin N.A., Disatnik M.H.,
RA   Mochly-Rosen D., Murnane J.P., Christman M.F.;
RT   "The product of the ataxia-telangiectasia group D complementing gene,
RT   ATDC, interacts with a protein kinase C substrate and inhibitor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7824-7828(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cervix, and Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA], X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS), AND
RP   SUBUNIT.
RX   PubMed=8643579; DOI=10.1073/pnas.93.11.5357;
RA   Lima C.D., Klein M.G., Weinstein I.B., Hendrickson W.A.;
RT   "Three-dimensional structure of human protein kinase C interacting
RT   protein 1, a member of the HIT family of proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:5357-5362(1996).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-24.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [8]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=15703176; DOI=10.1074/jbc.M500434200;
RA   Chou T.F., Bieganowski P., Shilinski K., Cheng J., Brenner C.,
RA   Wagner C.R.;
RT   "31P NMR and genetic analysis establish hinT as the only Escherchia
RT   coli purine nucleoside phosphoramidase and as essential for growth
RT   under high salt conditions.";
RL   J. Biol. Chem. 280:15356-15361(2005).
RN   [9]
RP   INTERACTION WITH RUVBL1 AND RUVBL2, SUBCELLULAR LOCATION, AND
RP   FUNCTION.
RX   PubMed=16014379; DOI=10.1242/jcs.02437;
RA   Weiske J., Huber O.;
RT   "The histidine triad protein Hint1 interacts with Pontin and Reptin
RT   and inhibits TCF-beta-catenin-mediated transcription.";
RL   J. Cell Sci. 118:3117-3129(2005).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, MUTAGENESIS OF GLY-105 AND SER-107,
RP   CHARACTERIZATION OF VARIANT NMAN ASN-112, SUBUNIT, AND IDENTIFICATION
RP   IN A COMPLEX WITH KAT5.
RX   PubMed=16835243; DOI=10.1074/jbc.M513452200;
RA   Weiske J., Huber O.;
RT   "The histidine triad protein Hint1 triggers apoptosis independent of
RT   its enzymatic activity.";
RL   J. Biol. Chem. 281:27356-27366(2006).
RN   [11]
RP   CATALYTIC ACTIVITY, SUBUNIT, AND MUTAGENESIS OF VAL-97.
RX   PubMed=17337452; DOI=10.1074/jbc.M606972200;
RA   Chou T.F., Tikh I.B., Horta B.A., Ghosh B., De Alencastro R.B.,
RA   Wagner C.R.;
RT   "Engineered monomeric human histidine triad nucleotide-binding protein
RT   1 hydrolyzes fluorogenic acyl-adenylate and lysyl-tRNA synthetase-
RT   generated lysyl-adenylate.";
RL   J. Biol. Chem. 282:15137-15147(2007).
RN   [12]
RP   INTERACTION WITH CDC34 AND RBX1, IDENTIFICATION IN A UBIQUITIN LIGASE
RP   COMPLEX, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=19112177; DOI=10.1074/jbc.M804531200;
RA   Cen B., Li H., Weinstein I.B.;
RT   "Histidine triad nucleotide-binding protein 1 up-regulates cellular
RT   levels of p27KIP1 by targeting ScfSKP2 ubiquitin ligase and Src.";
RL   J. Biol. Chem. 284:5265-5276(2009).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-21 AND LYS-30, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   IDENTIFICATION IN A COMPLEX WITH MITF AND CTNNB1, AND FUNCTION.
RX   PubMed=22647378; DOI=10.4161/cc.20765;
RA   Genovese G., Ghosh P., Li H., Rettino A., Sioletic S., Cittadini A.,
RA   Sgambato A.;
RT   "The tumor suppressor HINT1 regulates MITF and beta-catenin
RT   transcriptional activity in melanoma cells.";
RL   Cell Cycle 11:2206-2215(2012).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) IN COMPLEXES WITH AMP;
RP   ADENOSINE METHYLENE DIPHOSPHATE AND ADENOSINE-5'-DITUNGSTATE,
RP   CATALYTIC ACTIVITY, FUNCTION, ACTIVE SITE, AND SUBUNIT.
RX   PubMed=9323207; DOI=10.1126/science.278.5336.286;
RA   Lima C.D., Klein M.G., Hendrickson W.A.;
RT   "Structure-based analysis of catalysis and substrate definition in the
RT   HIT protein family.";
RL   Science 278:286-290(1997).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.38 ANGSTROMS) IN COMPLEX WITH AMP, AND
RP   SUBUNIT.
RX   PubMed=22869114; DOI=10.1107/S1744309112029491;
RA   Dolot R., Ozga M., Wlodarczyk A., Krakowiak A., Nawrot B.;
RT   "A new crystal form of human histidine triad nucleotide-binding
RT   protein 1 (hHINT1) in complex with adenosine 5'-monophosphate at 1.38
RT   A resolution.";
RL   Acta Crystallogr. F 68:883-888(2012).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.52 ANGSTROMS) IN COMPLEXES WITH SUBSTRATE
RP   ANALOGS, CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, AND MUTAGENESIS OF
RP   HIS-114 AND TRP-123.
RX   PubMed=22329685; DOI=10.1021/jp212457w;
RA   Wang J., Fang P., Schimmel P., Guo M.;
RT   "Side chain independent recognition of aminoacyl adenylates by the
RT   Hint1 transcription suppressor.";
RL   J. Phys. Chem. B 116:6798-6805(2012).
RN   [20]
RP   VARIANTS NMAN PRO-37; ARG-51; ARG-84; VAL-89; ASP-93 AND ASN-112, AND
RP   CHARACTERIZATION OF VARIANTS NMAN PRO-37; ARG-51; ARG-84 AND ASN-112.
RX   PubMed=22961002; DOI=10.1038/ng.2406;
RA   Zimon M., Baets J., Almeida-Souza L., De Vriendt E., Nikodinovic J.,
RA   Parman Y., Battaloglu E., Matur Z., Guergueltcheva V., Tournev I.,
RA   Auer-Grumbach M., De Rijk P., Petersen B.S., Muller T., Fransen E.,
RA   Van Damme P., Loscher W.N., Barisic N., Mitrovic Z., Previtali S.C.,
RA   Topaloglu H., Bernert G., Beleza-Meireles A., Todorovic S.,
RA   Savic-Pavicevic D., Ishpekova B., Lechner S., Peeters K., Ooms T.,
RA   Hahn A.F., Zuchner S., Timmerman V., Van Dijck P., Rasic V.M.,
RA   Janecke A.R., De Jonghe P., Jordanova A.;
RT   "Loss-of-function mutations in HINT1 cause axonal neuropathy with
RT   neuromyotonia.";
RL   Nat. Genet. 44:1080-1083(2012).
CC   -!- FUNCTION: Hydrolyzes purine nucleotide phosphoramidates with a
CC       single phosphate group, including adenosine 5'monophosphoramidate
CC       (AMP-NH2), adenosine 5'monophosphomorpholidate (AMP-morpholidate)
CC       and guanosine 5'monophosphomorpholidate (GMP-morpholidate).
CC       Hydrolyzes lysyl-AMP (AMP-N-epsilon-(N-alpha-acetyl lysine methyl
CC       ester)) generated by lysine tRNA ligase, as well as Met-AMP, His-
CC       AMP and Asp-AMP, lysyl-GMP (GMP-N-epsilon-(N-alpha-acetyl lysine
CC       methyl ester)) and AMP-N-alanine methyl ester. Can also convert
CC       adenosine 5'-O-phosphorothioate and guanosine 5'-O-
CC       phosphorothioate to the corresponding nucleoside 5'-O-phosphates
CC       with concomitant release of hydrogen sulfide. In addition,
CC       functions as scaffolding protein that modulates transcriptional
CC       activation by the LEF1/TCF1-CTNNB1 complex and by the complex
CC       formed with MITF and CTNNB1. Modulates p53/TP53 levels and
CC       p53/TP53-mediated apoptosis. Modulates proteasomal degradation of
CC       target proteins by the SCF (SKP2-CUL1-F-box protein) E3 ubiquitin-
CC       protein ligase complex. {ECO:0000269|PubMed:15703176,
CC       ECO:0000269|PubMed:16014379, ECO:0000269|PubMed:16835243,
CC       ECO:0000269|PubMed:19112177, ECO:0000269|PubMed:22329685,
CC       ECO:0000269|PubMed:22647378, ECO:0000269|PubMed:9323207}.
CC   -!- SUBUNIT: Homodimer. Interacts with CDK7. Interacts with RUVBL1 and
CC       RUVBL2 and is associated with the LEF1/TCF1-CTNNB1 complex and
CC       with a KAT5 histone acetyltransferase complex. Identified in a
CC       complex with MITF and CTNNB1. Interacts with CDC34 and RBX1, and
CC       is part of a SCF (SKP2-CUL1-F-box protein) E3 ubiquitin-protein
CC       ligase complex. {ECO:0000269|PubMed:16014379,
CC       ECO:0000269|PubMed:16835243, ECO:0000269|PubMed:17337452,
CC       ECO:0000269|PubMed:19112177, ECO:0000269|PubMed:22329685,
CC       ECO:0000269|PubMed:22647378, ECO:0000269|PubMed:22869114,
CC       ECO:0000269|PubMed:8643579, ECO:0000269|PubMed:9323207}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Interaction with
CC       CDK7 leads to a more nuclear localization.
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- DISEASE: Neuromyotonia and axonal neuropathy, autosomal recessive
CC       (NMAN) [MIM:137200]: An autosomal recessive neurologic disorder
CC       characterized by onset in the first or second decade of a
CC       peripheral axonal neuropathy predominantly affecting motor more
CC       than sensory nerves. The axonal neuropathy is reminiscent of
CC       Charcot-Marie-Tooth disease type 2 and distal hereditary motor
CC       neuropathy. Individuals with NMAN also have delayed muscle
CC       relaxation and action myotonia associated with neuromyotonic
CC       discharges on needle EMG resulting from hyperexcitability of the
CC       peripheral nerves. {ECO:0000269|PubMed:22961002}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the HINT family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 HIT domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00464}.
CC   -!- CAUTION: Was originally thought to be a protein kinase C inhibitor
CC       and to bind zinc in solution. Both seem to be incorrect.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U27143; AAA82926.1; -; mRNA.
DR   EMBL; U51004; AAC71077.1; -; mRNA.
DR   EMBL; AK026557; BAB15500.1; -; mRNA.
DR   EMBL; CR457048; CAG33329.1; -; mRNA.
DR   EMBL; BC001287; AAH01287.1; -; mRNA.
DR   EMBL; BC007090; AAH07090.1; -; mRNA.
DR   CCDS; CCDS4147.1; -.
DR   PIR; S72501; S72501.
DR   RefSeq; NP_005331.1; NM_005340.6.
DR   UniGene; Hs.483305; -.
DR   PDB; 1AV5; X-ray; 2.00 A; A/B=2-126.
DR   PDB; 1KPA; X-ray; 2.00 A; A/B=2-126.
DR   PDB; 1KPB; X-ray; 2.00 A; A/B=2-126.
DR   PDB; 1KPC; X-ray; 2.20 A; A/B/C/D=2-126.
DR   PDB; 1KPE; X-ray; 1.80 A; A/B=2-126.
DR   PDB; 1KPF; X-ray; 1.50 A; A=2-126.
DR   PDB; 3TW2; X-ray; 1.38 A; A/B=1-126.
DR   PDB; 4EQE; X-ray; 1.52 A; A/B=1-126.
DR   PDB; 4EQG; X-ray; 1.52 A; A/B=1-126.
DR   PDB; 4EQH; X-ray; 1.67 A; A/B=1-126.
DR   PDBsum; 1AV5; -.
DR   PDBsum; 1KPA; -.
DR   PDBsum; 1KPB; -.
DR   PDBsum; 1KPC; -.
DR   PDBsum; 1KPE; -.
DR   PDBsum; 1KPF; -.
DR   PDBsum; 3TW2; -.
DR   PDBsum; 4EQE; -.
DR   PDBsum; 4EQG; -.
DR   PDBsum; 4EQH; -.
DR   ProteinModelPortal; P49773; -.
DR   SMR; P49773; 11-126.
DR   BioGrid; 109341; 18.
DR   IntAct; P49773; 7.
DR   MINT; MINT-5001048; -.
DR   STRING; 9606.ENSP00000304229; -.
DR   BindingDB; P49773; -.
DR   ChEMBL; CHEMBL5878; -.
DR   DrugBank; DB00131; Adenosine monophosphate.
DR   PhosphoSite; P49773; -.
DR   DMDM; 1708543; -.
DR   OGP; P49773; -.
DR   UCD-2DPAGE; P49773; -.
DR   MaxQB; P49773; -.
DR   PaxDb; P49773; -.
DR   PeptideAtlas; P49773; -.
DR   PRIDE; P49773; -.
DR   Ensembl; ENST00000304043; ENSP00000304229; ENSG00000169567.
DR   GeneID; 3094; -.
DR   KEGG; hsa:3094; -.
DR   UCSC; uc003kve.4; human.
DR   CTD; 3094; -.
DR   GeneCards; GC05M130522; -.
DR   HGNC; HGNC:4912; HINT1.
DR   HPA; HPA036488; -.
DR   HPA; HPA044577; -.
DR   MIM; 137200; phenotype.
DR   MIM; 601314; gene.
DR   neXtProt; NX_P49773; -.
DR   Orphanet; 324442; Autosomal recessive axonal neuropathy with neuromyotonia.
DR   PharmGKB; PA29286; -.
DR   eggNOG; COG0537; -.
DR   GeneTree; ENSGT00510000046448; -.
DR   HOGENOM; HOG000061064; -.
DR   HOVERGEN; HBG051906; -.
DR   InParanoid; P49773; -.
DR   KO; K02503; -.
DR   OMA; FRIMNNC; -.
DR   OrthoDB; EOG75QR5T; -.
DR   PhylomeDB; P49773; -.
DR   TreeFam; TF314862; -.
DR   SABIO-RK; P49773; -.
DR   ChiTaRS; HINT1; human.
DR   EvolutionaryTrace; P49773; -.
DR   GeneWiki; HINT1; -.
DR   GenomeRNAi; 3094; -.
DR   NextBio; 12279; -.
DR   PRO; PR:P49773; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; P49773; -.
DR   CleanEx; HS_HINT1; -.
DR   ExpressionAtlas; P49773; baseline and differential.
DR   Genevestigator; P49773; -.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005856; C:cytoskeleton; TAS:ProtInc.
DR   GO; GO:0070062; C:extracellular vesicular exosome; IDA:UniProtKB.
DR   GO; GO:0000118; C:histone deacetylase complex; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0016787; F:hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0005080; F:protein kinase C binding; TAS:ProtInc.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:0009154; P:purine ribonucleotide catabolic process; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.428.10; -; 1.
DR   InterPro; IPR019808; Histidine_triad_CS.
DR   InterPro; IPR001310; Histidine_triad_HIT.
DR   InterPro; IPR011146; HIT-like.
DR   PANTHER; PTHR23089; PTHR23089; 1.
DR   Pfam; PF01230; HIT; 1.
DR   PRINTS; PR00332; HISTRIAD.
DR   SUPFAM; SSF54197; SSF54197; 1.
DR   PROSITE; PS00892; HIT_1; 1.
DR   PROSITE; PS51084; HIT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Hydrolase; Neuropathy;
KW   Nucleotide-binding; Nucleus; Reference proteome; Transcription;
KW   Transcription regulation.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:12665801,
FT                                ECO:0000269|PubMed:22814378}.
FT   CHAIN         2    126       Histidine triad nucleotide-binding
FT                                protein 1.
FT                                /FTId=PRO_0000109781.
FT   DOMAIN       18    126       HIT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00464}.
FT   NP_BIND      43     44       Purine nucleotide phosphoramidate.
FT   NP_BIND     105    107       Purine nucleotide phosphoramidate.
FT   NP_BIND     112    114       Purine nucleotide phosphoramidate.
FT   MOTIF       110    114       Histidine triad motif.
FT   ACT_SITE    112    112       Tele-AMP-histidine intermediate.
FT                                {ECO:0000269|PubMed:9323207}.
FT   BINDING      99     99       Purine nucleotide phosphoramidate.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000269|PubMed:22814378}.
FT   MOD_RES      21     21       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   MOD_RES      30     30       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   VARIANT      37     37       R -> P (in NMAN; negligible protein
FT                                expression due to post-translational
FT                                degradation; dbSNP:rs149782619).
FT                                {ECO:0000269|PubMed:22961002}.
FT                                /FTId=VAR_069212.
FT   VARIANT      51     51       H -> R (in NMAN; no mutant protein is
FT                                detected due to post-translational
FT                                degradation).
FT                                {ECO:0000269|PubMed:22961002}.
FT                                /FTId=VAR_069213.
FT   VARIANT      84     84       C -> R (in NMAN; negligible protein
FT                                expression due to post-translational
FT                                degradation).
FT                                {ECO:0000269|PubMed:22961002}.
FT                                /FTId=VAR_069214.
FT   VARIANT      89     89       G -> V (in NMAN).
FT                                {ECO:0000269|PubMed:22961002}.
FT                                /FTId=VAR_069215.
FT   VARIANT      93     93       G -> D (in NMAN).
FT                                {ECO:0000269|PubMed:22961002}.
FT                                /FTId=VAR_069216.
FT   VARIANT     112    112       H -> N (in NMAN; the enzyme has no
FT                                residual activity although the mutant
FT                                protein is expressed at normal levels).
FT                                {ECO:0000269|PubMed:16835243,
FT                                ECO:0000269|PubMed:22961002}.
FT                                /FTId=VAR_069217.
FT   MUTAGEN      97     97       V->D,E: Loss of dimerization. Strongly
FT                                reduced enzyme activity.
FT                                {ECO:0000269|PubMed:17337452}.
FT   MUTAGEN     105    105       G->A: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:16835243}.
FT   MUTAGEN     107    107       S->A: Reduces enzyme activity.
FT                                {ECO:0000269|PubMed:16835243}.
FT   MUTAGEN     114    114       H->A: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:22329685}.
FT   MUTAGEN     123    123       W->A: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:22329685}.
FT   CONFLICT     25     25       K -> E (in Ref. 3; BAB15500).
FT                                {ECO:0000305}.
FT   HELIX        18     23       {ECO:0000244|PDB:3TW2}.
FT   STRAND       31     34       {ECO:0000244|PDB:3TW2}.
FT   STRAND       36     42       {ECO:0000244|PDB:3TW2}.
FT   STRAND       47     58       {ECO:0000244|PDB:3TW2}.
FT   HELIX        63     65       {ECO:0000244|PDB:3TW2}.
FT   HELIX        68     70       {ECO:0000244|PDB:3TW2}.
FT   HELIX        71     87       {ECO:0000244|PDB:3TW2}.
FT   STRAND       94    100       {ECO:0000244|PDB:3TW2}.
FT   HELIX       101    104       {ECO:0000244|PDB:3TW2}.
FT   STRAND      108    110       {ECO:0000244|PDB:3TW2}.
FT   STRAND      113    119       {ECO:0000244|PDB:3TW2}.
SQ   SEQUENCE   126 AA;  13802 MW;  6C2B0119370384AA CRC64;
     MADEIAKAQV ARPGGDTIFG KIIRKEIPAK IIFEDDRCLA FHDISPQAPT HFLVIPKKHI
     SQISVAEDDD ESLLGHLMIV GKKCAADLGL NKGYRMVVNE GSDGGQSVYH VHLHVLGGRQ
     MHWPPG
//
